



## **Necrostatin 2**

**Catalog No: tcsc1511** 

Available Sizes		
Size: 5mg		
Size: 10mg		
Size: 50mg		
Specifications		
<b>CAS No:</b> 852391-19-6		
Formula: C <sub>13</sub> H <sub>12</sub> CIN <sub>3</sub> O <sub>2</sub>		
Pathway: Apoptosis		
Target: TNF Receptor		
Purity / Grade: >98%		
Solubility: DMSO : ≥ 100 mg/mL (360.09 mM)		
Observed Molecular Weight:		

## **Product Description**

277.71

Necrostatin 2 is a potent **necroptosis** inhibitor.  $\mathbf{EC}_{50}$  for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with  $\mathbf{TNF}$ - $\alpha$ 



is  $0.05 \mu M$ .

IC50 & Target: Necroptosis<sup>[1]</sup>

In Vitro: Evaluation of necroptosis inhibitory activity is performed using a FADD-deficient variant of human Jurkat T cells treated with TNF- $\alpha$ . Utilizing these conditions the cells efficiently undergo necroptosis, which is completely and selectively inhibited by Necrostatin 2 (EC $_{50}$ =50 nM). Necrostatin 2 shows activity in a broad range of necroptosis cellular systems<sup>[1]</sup>. Necrostatin 2 at 30  $\mu$ M completely protects L929 cells from TNF- $\alpha$ -induced necroptosis. In addition to TNF- $\alpha$ , the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD.fmk) has also been found to induce necrosis in L929 cells, which is efficiently inhibited by Necrostatin 2<sup>[2]</sup>. EC $_{50}$  for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF- $\alpha$  is 0.05  $\mu$ M<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!